CBIO vs. LGND, BCRX, FOLD, INVA, CLDX, DVAX, MNKD, NVAX, OPK, and GERN
Should you be buying GlycoMimetics stock or one of its competitors? The main competitors of GlycoMimetics include Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Innoviva (INVA), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry.
GlycoMimetics vs. Its Competitors
GlycoMimetics (NASDAQ:CBIO) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.
GlycoMimetics has a net margin of 0.00% compared to Ligand Pharmaceuticals' net margin of -73.07%. Ligand Pharmaceuticals' return on equity of -7.83% beat GlycoMimetics' return on equity.
75.2% of GlycoMimetics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 8.7% of GlycoMimetics shares are held by company insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
GlycoMimetics has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Ligand Pharmaceuticals has higher revenue and earnings than GlycoMimetics. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than GlycoMimetics, indicating that it is currently the more affordable of the two stocks.
In the previous week, GlycoMimetics and GlycoMimetics both had 3 articles in the media. Ligand Pharmaceuticals' average media sentiment score of 1.67 beat GlycoMimetics' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.
Ligand Pharmaceuticals received 245 more outperform votes than GlycoMimetics when rated by MarketBeat users. Likewise, 70.39% of users gave Ligand Pharmaceuticals an outperform vote while only 68.36% of users gave GlycoMimetics an outperform vote.
GlycoMimetics currently has a consensus price target of $22.00, suggesting a potential upside of 43.79%. Ligand Pharmaceuticals has a consensus price target of $146.14, suggesting a potential upside of 27.11%. Given GlycoMimetics' stronger consensus rating and higher possible upside, research analysts clearly believe GlycoMimetics is more favorable than Ligand Pharmaceuticals.
Summary
Ligand Pharmaceuticals beats GlycoMimetics on 10 of the 17 factors compared between the two stocks.
Get GlycoMimetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
GlycoMimetics Competitors List
Related Companies and Tools
This page (NASDAQ:CBIO) was last updated on 6/23/2025 by MarketBeat.com Staff
Buy CBIO Stock Free CBIO Stock Alerts